402 related articles for article (PubMed ID: 30978155)
1. Intermittent Versus Continuous PEG-Asparaginase to Reduce Asparaginase-Associated Toxicities: A NOPHO ALL2008 Randomized Study.
Albertsen BK; Grell K; Abrahamsson J; Lund B; Vettenranta K; Jónsson ÓG; Frandsen TL; Wolthers BO; Heyman M; Schmiegelow K
J Clin Oncol; 2019 Jul; 37(19):1638-1646. PubMed ID: 30978155
[TBL] [Abstract][Full Text] [Related]
2. Intravenous pegylated asparaginase versus intramuscular native Escherichia coli L-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial.
Place AE; Stevenson KE; Vrooman LM; Harris MH; Hunt SK; O'Brien JE; Supko JG; Asselin BL; Athale UH; Clavell LA; Cole PD; Kelly KM; Laverdiere C; Leclerc JM; Michon B; Schorin MA; Welch JJ; Lipshultz SE; Kutok JL; Blonquist TM; Neuberg DS; Sallan SE; Silverman LB
Lancet Oncol; 2015 Dec; 16(16):1677-90. PubMed ID: 26549586
[TBL] [Abstract][Full Text] [Related]
3. PEG-asparaginase allergy in children with acute lymphoblastic leukemia in the NOPHO ALL2008 protocol.
Henriksen LT; Harila-Saari A; Ruud E; Abrahamsson J; Pruunsild K; Vaitkeviciene G; Jónsson ÓG; Schmiegelow K; Heyman M; Schrøder H; Albertsen BK;
Pediatr Blood Cancer; 2015 Mar; 62(3):427-33. PubMed ID: 25418987
[TBL] [Abstract][Full Text] [Related]
4. Asparaginase-associated pancreatitis in children with acute lymphoblastic leukaemia in the NOPHO ALL2008 protocol.
Raja RA; Schmiegelow K; Albertsen BK; Prunsild K; Zeller B; Vaitkeviciene G; Abrahamsson J; Heyman M; Taskinen M; Harila-Saari A; Kanerva J; Frandsen TL;
Br J Haematol; 2014 Apr; 165(1):126-33. PubMed ID: 24428625
[TBL] [Abstract][Full Text] [Related]
5. PEG-asparaginase treatment regimens for acute lymphoblastic leukaemia in children: a network meta-analysis.
Lynggaard LS; Rank CU; Als-Nielsen B; Hoejfeldt SG; Heyman M; Schmiegelow K; Albertsen BK
Cochrane Database Syst Rev; 2023 May; 5(5):CD014570. PubMed ID: 37260073
[TBL] [Abstract][Full Text] [Related]
6. Hepatic sinusoidal obstruction syndrome during maintenance therapy of childhood acute lymphoblastic leukemia is associated with continuous asparaginase therapy and mercaptopurine metabolites.
Toksvang LN; De Pietri S; Nielsen SN; Nersting J; Albertsen BK; Wehner PS; Rosthøj S; Lähteenmäki PM; Nilsson D; Nystad TA; Grell K; Frandsen TL; Schmiegelow K
Pediatr Blood Cancer; 2017 Sep; 64(9):. PubMed ID: 28423235
[TBL] [Abstract][Full Text] [Related]
7. Asparaginase-Associated Pancreatitis in Acute Lymphoblastic Leukemia: Results From the NOPHO ALL2008 Treatment of Patients 1-45 Years of Age.
Rank CU; Wolthers BO; Grell K; Albertsen BK; Frandsen TL; Overgaard UM; Toft N; Nielsen OJ; Wehner PS; Harila-Saari A; Heyman MM; Malmros J; Abrahamsson J; Norén-Nyström U; Tomaszewska-Toporska B; Lund B; Jarvis KB; Quist-Paulsen P; Vaitkevičienė GE; Griškevičius L; Taskinen M; Wartiovaara-Kautto U; Lepik K; Punab M; Jónsson ÓG; Schmiegelow K
J Clin Oncol; 2020 Jan; 38(2):145-154. PubMed ID: 31770057
[TBL] [Abstract][Full Text] [Related]
8. Continuous PEGasparaginase Dosing Reduces Hypersensitivity Reactions in Pediatric ALL: A Dutch Childhood Oncology Group ALL11 Randomized Trial.
van der Sluis IM; Brigitha LJ; Fiocco M; de Groot-Kruseman HA; Bierings M; van den Bos C; de Haas V; Hoogerbrugge PM; Tissing WJE; Veening MA; Pieters R
J Clin Oncol; 2024 May; 42(14):1676-1686. PubMed ID: 38306592
[TBL] [Abstract][Full Text] [Related]
9. Prolonged first-line PEG-asparaginase treatment in pediatric acute lymphoblastic leukemia in the NOPHO ALL2008 protocol-Pharmacokinetics and antibody formation.
Tram Henriksen L; Gottschalk Højfeldt S; Schmiegelow K; Frandsen TL; Skov Wehner P; Schrøder H; Klug Albertsen B;
Pediatr Blood Cancer; 2017 Dec; 64(12):. PubMed ID: 28660740
[TBL] [Abstract][Full Text] [Related]
10. Relapse risk following truncation of pegylated asparaginase in childhood acute lymphoblastic leukemia.
Gottschalk Højfeldt S; Grell K; Abrahamsson J; Lund B; Vettenranta K; Jónsson ÓG; Frandsen TL; Wolthers BO; Marquart HV; Vaitkeviciene G; Lepik K; Heyman M; Schmiegelow K; Albertsen BK
Blood; 2021 Apr; 137(17):2373-2382. PubMed ID: 33150360
[TBL] [Abstract][Full Text] [Related]
11. Asparaginase enzyme activity levels and toxicity in childhood acute lymphoblastic leukemia: a NOPHO ALL2008 study.
Lynggaard LS; Rank CU; Hansen SN; Gottschalk Højfeldt S; Henriksen LT; Jarvis KB; Ranta S; Niinimäki R; Harila-Saari A; Wolthers BO; Frandsen TL; Heyman M; Schmiegelow K; Albertsen BK
Blood Adv; 2022 Jan; 6(1):138-147. PubMed ID: 34625787
[TBL] [Abstract][Full Text] [Related]
12. Lower incidence of clinical allergy with PEG-asparaginase upfront versus the sequential use of native E. coli asparaginase followed by PEG-ASP in pediatric patients with acute lymphoblastic leukemia.
Mesegué M; Alonso-Saladrigues A; Pérez-Jaume S; Comes-Escoda A; Dapena JL; Faura A; Conde N; Català A; Ruiz-Llobet A; Zapico-Muñiz E; Camós M; Rives S
Hematol Oncol; 2021 Dec; 39(5):687-696. PubMed ID: 34397119
[TBL] [Abstract][Full Text] [Related]
13. Toxicity profile of repeated doses of PEG-asparaginase incorporated into a pediatric-type regimen for adult acute lymphoblastic leukemia.
Aldoss I; Douer D; Behrendt CE; Chaudhary P; Mohrbacher A; Vrona J; Pullarkat V
Eur J Haematol; 2016 Apr; 96(4):375-80. PubMed ID: 26095294
[TBL] [Abstract][Full Text] [Related]
14. Individualized Asparaginase Dosing in Childhood Acute Lymphoblastic Leukemia.
Kloos RQH; Pieters R; Jumelet FMV; de Groot-Kruseman HA; van den Bos C; van der Sluis IM
J Clin Oncol; 2020 Mar; 38(7):715-724. PubMed ID: 31922920
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic and pharmacodynamic properties of calaspargase pegol Escherichia coli L-asparaginase in the treatment of patients with acute lymphoblastic leukemia: results from Children's Oncology Group Study AALL07P4.
Angiolillo AL; Schore RJ; Devidas M; Borowitz MJ; Carroll AJ; Gastier-Foster JM; Heerema NA; Keilani T; Lane AR; Loh ML; Reaman GH; Adamson PC; Wood B; Wood C; Zheng HW; Raetz EA; Winick NJ; Carroll WL; Hunger SP
J Clin Oncol; 2014 Dec; 32(34):3874-82. PubMed ID: 25348002
[TBL] [Abstract][Full Text] [Related]
16. Prospective study of thromboembolism in 1038 children with acute lymphoblastic leukemia: a Nordic Society of Pediatric Hematology and Oncology (NOPHO) study.
Tuckuviene R; Ranta S; Albertsen BK; Andersson NG; Bendtsen MD; Frisk T; Gunnes MW; Helgestad J; Heyman MM; Jonsson OG; Mäkipernaa A; Pruunsild K; Tedgård U; Trakymiene SS; Ruud E
J Thromb Haemost; 2016 Mar; 14(3):485-94. PubMed ID: 26707629
[TBL] [Abstract][Full Text] [Related]
17. Cerebrospinal fluid asparagine depletion during pegylated asparaginase therapy in children with acute lymphoblastic leukaemia.
Henriksen LT; Nersting J; Raja RA; Frandsen TL; Rosthøj S; Schrøder H; Albertsen BK;
Br J Haematol; 2014 Jul; 166(2):213-20. PubMed ID: 24702187
[TBL] [Abstract][Full Text] [Related]
18. [Comparison of polyethylene glycol conjugated asparaginase and L-asparaginase for treatment of childhood acute lymphoblastic leukemia].
Cooperation Group of Phase II Clinical Trial of PEG-Asp
Zhonghua Xue Ye Xue Za Zhi; 2008 Jan; 29(1):29-33. PubMed ID: 18512312
[TBL] [Abstract][Full Text] [Related]
19. Weekly polyethylene glycol conjugated L-asparaginase compared with biweekly dosing produces superior induction remission rates in childhood relapsed acute lymphoblastic leukemia: a Pediatric Oncology Group Study.
Abshire TC; Pollock BH; Billett AL; Bradley P; Buchanan GR
Blood; 2000 Sep; 96(5):1709-15. PubMed ID: 10961868
[TBL] [Abstract][Full Text] [Related]
20. FDA drug approval summary: pegaspargase (oncaspar) for the first-line treatment of children with acute lymphoblastic leukemia (ALL).
Dinndorf PA; Gootenberg J; Cohen MH; Keegan P; Pazdur R
Oncologist; 2007 Aug; 12(8):991-8. PubMed ID: 17766659
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
